Compare Adaptive Biotechnologies Corp (ADPT) vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF (VTIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF — how do they compare? Adaptive Biotechnologies Corp trades at $25.41 (market cap $4.05B), while Vanguard Sht-Term Inflation-Protected Sec Idx ETF trades at $49.67. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, Vanguard Sht-Term Inflation-Protected Sec Idx ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | VTIP | |
|---|---|---|
Market Cap | $4.05B | — |
Sector | Health | — |
52-Week High | $25.45 | $50.75 |
52-Week Low | $12.15 | $49.39 |
Enterprise Value | $4.12B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.93, up 5.64% in 24 hours and near its 52-week high. The stock shows bullish technical momentum with improving fundamentals as revenue grew 55% year-over-year to $277M in 2025 while net losses narrowed significantly from -$159M to -$59M. The company's strategic shift to focus on its profitable MRD diagnostics business through a planned separation of Immune Medicine operations has driven investor optimism.
Outlook remains cautiously optimistic as ADPT transitions to a pure-play MRD company with strong gross margins exceeding 75%. While analyst consensus favors Buy ratings (65%), persistent net losses and high valuation multiples (P/S 12.6x, P/B 27.8x) present risks. The $25.50 price target suggests limited upside from current levels amid execution risks.
VTIP, the Vanguard Short-Term Inflation-Protected Securities ETF, trades at $49.67, up 0.08% with a bullish technical signal. The ETF focuses on short-term Treasury Inflation-Protected Securities, offering inflation hedging. Recent news highlights institutional buying and inflation concerns, with a dividend declared for July 2026. Technical indicators show mixed signals but overall positive momentum.
Outlook: VTIP provides inflation protection amid rising prices, with potential returns around 3.8% based on current inflation. Risks include interest rate volatility and Fed policy uncertainty. It suits investors seeking low-duration, inflation-linked income, but may underperform if inflation subsides unexpectedly.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Vanguard Sht-Term Inflation-Protected Sec Idx ETF
The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.
Read more on VTIP →
